Akers Biosciences, Inc. Issue of Equity (9469V)
November 08 2017 - 8:59AM
UK Regulatory
TIDMAKR
RNS Number : 9469V
Akers Biosciences, Inc.
08 November 2017
November 8, 2017
Akers Biosciences, Inc.
("Akers Bio" or the "Company")
Issue of Equity
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, has received conversion notices from warrant holders
in respect of the remaining 337,200 warrants, granted pursuant to
the March 2017 share placement (the "March 2017 Warrants"), to
convert into 337,200 common shares in the Company at an exercise
price of $1.00 per warrant (per the revised strike price terms
announced on October 13, 2017). Accordingly, the Company has
received further proceeds of $337,200.
The Company will apply for the admission of the 337,200 common
shares to AIM and this is expected to take place on November 13,
2017 ("Admission"). Following Admission, the Company's issued share
capital will consist of 9,920,552 common shares with no common
shares held in treasury. Therefore, the above figure of 9,920,552
may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Executive Chairman and Chief
Scientific Director
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEOKFDPNBDDFDK
(END) Dow Jones Newswires
November 08, 2017 08:59 ET (13:59 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Sep 2023 to Sep 2024